Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARYA Sciences Acquisition Corp VARYE · Entity 137308 | Director | July 12, 2021 | July 13, 2021 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Director | May 18, 2022 | May 28, 2022 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Director · President and CEO | October 07, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARYA Sciences Acquisition Corp V
Report date July 12, 2021 · Filed July 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-07-12 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
PROTHENA CORP PUBLIC LTD CO
Report date May 18, 2022 · Filed May 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.60 · Expires 2032-05-18 | Direct | 15,000 |
Reported balance
After 2022-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-18 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2023 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2023 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.
Relay Therapeutics, Inc.
Report date October 07, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 471,301 |
Reported balance
After 2026-10-07 transaction · row 1
1 source rowRow 1 · 2026-10-07 · Sale · Disposed 48,199 · Balance 471,301 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2: This transaction was executed in multiple trades at prices ranging from $17.87 to $18.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy The Patel Family Irrevocable Trust of 2019 | 199,548 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 199,548 F3: These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy The SSP Irrevocable Trust of 2020 | 687,355 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 687,355 F3: These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $17.87 to $18.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2026 Filed Oct 8, 2026 21:29 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 48,199 | $18.10 | $872,401.90 |
DisclosureSEC source: 0001193125-26-418096 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,301 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.87 to $18.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 20:12 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 48,199 | $18.94 | $912,889.06 |
DisclosureSEC source: 0001193125-26-386455 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 519,500 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.33 to $19.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 20:17 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 48,199 | $20.33 | $979,885.67 |
DisclosureSEC source: 0001193125-26-355502 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 567,699 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.56 to $20.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 21:08 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 48,199 | $19.58 | $943,736.42 |
DisclosureSEC source: 0001193125-26-298681 · ownership.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 615,898 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $18.52 to $20.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 30, 2026 Filed Jul 8, 2026 21:08 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 3,056 | $6.95 | $21,239.20 |
DisclosureSEC source: 0001193125-26-298681 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 664,097 F1 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on January 2, 2026. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 1,450,000 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001193125-26-014109 · ownership.xml · derivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,450,000 Underlying: Common Stock · 1,450,000 shares Expires 2036-01-12 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 13, 2026, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 21:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 43,168 | $7.82 | $337,573.76 |
DisclosureSEC source: 0001193125-26-006328 · ownership.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 661,041 F4 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 136,854 shares of RSUs on January 5, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. Read SEC document |
| December 31, 2025 Filed Jan 7, 2026 21:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 994 | $2.99 | $2,972.06 |
DisclosureSEC source: 0001193125-26-006328 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 704,209 F1 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on July 1, 2025. F3 · balance_after: Includes 136,854 shares underlying restricted stock units ("RSUs"). Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 21:10 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 62,073 | $7.00 | $434,511.00 |
DisclosureSEC source: 0001193125-25-264700 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 703,215 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 136,853 shares of restricted stock units ("RSUs") on October 31, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 136,854 shares underlying RSUs. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 20:55 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 18,639 | $3.57 | $66,541.23 |
DisclosureSEC source: 0000950170-25-095093 · ownership.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 765,288 F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 41,558 shares of RSUs on July 8, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4 · balance_after: Includes 273,707 shares underlying RSUs. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 20:55 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 42,740 | $3.57 | $152,581.80 |
DisclosureSEC source: 0000950170-25-095093 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 783,927 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 95,295 shares of restricted stock units ("RSUs") on July 8, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 315,265 shares underlying RSUs. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:59 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 5,000 | $2.94 | $14,700.00 |
DisclosureSEC source: 0000950170-25-092305 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 826,667 F1 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025. F3 · balance_after: Includes 410,560 shares underlying RSUs. Read SEC document |
| April 23, 2025 Filed Apr 24, 2025 20:03 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 18,653 | $2.97 | $55,399.41 |
DisclosureSEC source: 0000950170-25-057996 · ownership.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 821,667 F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 41,558 shares of RSUs on April 22, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4 · balance_after: Includes 410,560 shares underlying RSUs. Read SEC document |
| April 23, 2025 Filed Apr 24, 2025 20:03 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 42,769 | $2.97 | $127,023.93 |
DisclosureSEC source: 0000950170-25-057996 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 840,320 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 95,295 shares of restricted stock units ("RSUs") on April 22, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 452,118 shares underlying RSUs. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 01:56 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 75,324 | $3.70 | $278,698.80 |
DisclosureSEC source: 0000950170-25-020272 · ownership.xml · nonDerivative · entry 3 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 883,089 F5 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 166,232 shares of RSUs on February 12, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F6 · balance_after: Includes 547,413 shares underlying RSUs. Read SEC document |
| February 11, 2025 Filed Feb 14, 2025 01:56 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 332,465 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-020272 · ownership.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 958,413 F3 · shares: Represents RSUs granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F4 · balance_after: Includes 713,645 shares underlying RSUs. Read SEC document |
| February 11, 2025 Filed Feb 14, 2025 01:56 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 140,182 | $3.85 | $539,700.70 |
DisclosureSEC source: 0000950170-25-020272 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 625,948 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 381,180 shares of restricted stock units ("RSUs") on February 10, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 381,180 shares underlying RSUs. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 00:01 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 125,000 | $4.78 | $597,500.00 |
DisclosureSEC source: 0000950170-25-008451 · ownership.xml · nonDerivative · entry 3 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By The Patel Family Irrevocable Trust of 2019 Disclosed balance after: 199,548 F1 · shares: These shares were sold by the Patel Family Irrevocable Trust of 2019 (the "Trust") pursuant to a Rule 10b5-1 trading plan adopted by the Trust on August 7, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $4.62 to $4.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: These shares are held in the Trust for the benefit of the reporting person's family members. An independent trustee is trustee of the Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 00:01 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 125,000 | $4.80 | $600,000.00 |
DisclosureSEC source: 0000950170-25-008451 · ownership.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By The Patel Family Irrevocable Trust of 2019 Disclosed balance after: 324,548 F1 · shares: These shares were sold by the Patel Family Irrevocable Trust of 2019 (the "Trust") pursuant to a Rule 10b5-1 trading plan adopted by the Trust on August 7, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $4.65 to $4.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: These shares are held in the Trust for the benefit of the reporting person's family members. An independent trustee is trustee of the Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 00:01 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 125,000 | $4.52 | $565,000.00 |
DisclosureSEC source: 0000950170-25-008451 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By The Patel Family Irrevocable Trust of 2019 Disclosed balance after: 449,548 F1 · shares: These shares were sold by the Patel Family Irrevocable Trust of 2019 (the "Trust") pursuant to a Rule 10b5-1 trading plan adopted by the Trust on August 7, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $4.35 to $4.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: These shares are held in the Trust for the benefit of the reporting person's family members. An independent trustee is trustee of the Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 10, 2025 Filed Jan 15, 2025 02:00 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 1,105,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0000950170-25-005566 · ownership.xml · derivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,105,000 Underlying: Common Stock · 1,105,000 shares Expires 2035-01-09 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 10, 2025, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:51 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 100,000 | $5.00 | $500,000.00 |
DisclosureSEC source: 0000950170-24-137960 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By The Patel Family Irrevocable Trust of 2019 Disclosed balance after: 574,548 F1 · shares: These shares were sold by the Patel Family Irrevocable Trust of 2019 (the "Trust") pursuant to a Rule 10b5-1 trading plan adopted by the Trust on August 7, 2024. F2 · ownership.nature: These shares are held in the Trust for the benefit of the reporting person's family members. An independent trustee is trustee of the Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 26, 2024 Filed Jul 29, 2024 22:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,706 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000950170-24-087435 · ownership.xml · derivative · entry 8 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 482,073 Underlying: Common Stock · 36,706 shares Expires 2029-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024. F6 · derivative.exercise_date: The shares underlying this option vested in sixteen (16) equal quarterly installments after April 23, 2019. Read SEC document |
| July 26, 2024 Filed Jul 29, 2024 22:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 36,706 | $9.07 | $332,923.42 |
DisclosureSEC source: 0000950170-24-087435 · ownership.xml · nonDerivative · entry 4 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 766,130 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $9.00 to $9.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 762,360 shares underlying restricted stock units. Read SEC document |
| July 26, 2024 Filed Jul 29, 2024 22:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 36,706 | $5.04 | $184,998.24 |
DisclosureSEC source: 0000950170-24-087435 · ownership.xml · nonDerivative · entry 3 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 802,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024. F2 · balance_after: Includes 762,360 shares underlying restricted stock units. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 22:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000950170-24-087435 · ownership.xml · derivative · entry 7 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 518,779 Underlying: Common Stock · 50,000 shares Expires 2029-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024. F6 · derivative.exercise_date: The shares underlying this option vested in sixteen (16) equal quarterly installments after April 23, 2019. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 22:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 50,000 | $9.16 | $458,000.00 |
DisclosureSEC source: 0000950170-24-087435 · ownership.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 766,130 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $9.00 to $9.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 762,360 shares underlying restricted stock units. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 22:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 50,000 | $5.04 | $252,000.00 |
DisclosureSEC source: 0000950170-24-087435 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 816,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024. F2 · balance_after: Includes 762,360 shares underlying restricted stock units. Read SEC document |
| June 30, 2024 Filed Jul 1, 2024 20:43 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 2,108 | $5.54 | $11,678.32 |
DisclosureSEC source: 0000950170-24-079693 · ownership.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 766,130 F1 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 28, 2024. F3 · balance_after: Includes 762,360 shares underlying restricted stock units. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:19 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 762,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001843 · doc4.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 764,022 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · balance_after: Includes 762,360 shares underlying RSUs. Read SEC document |
| June 30, 2023 Filed Sep 29, 2023 21:27 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 1,662 | $10.68 | $17,750.16 |
DisclosureSEC source: 0001209191-23-050874 · doc4.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,662 F1 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2023. Read SEC document |
| February 09, 2023 Filed Feb 9, 2023 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-23-008072 · doc4.xml · derivative · entry 11 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,779 Underlying: Common Stock · 14,000 shares Expires 2029-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F6 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after April 23, 2019, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| February 09, 2023 Filed Feb 9, 2023 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $20.55 | $287,700.00 |
DisclosureSEC source: 0001209191-23-008072 · doc4.xml · nonDerivative · entry 6 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $20.25 to $20.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 09, 2023 Filed Feb 9, 2023 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $5.04 | $70,560.00 |
DisclosureSEC source: 0001209191-23-008072 · doc4.xml · nonDerivative · entry 5 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| February 08, 2023 Filed Feb 9, 2023 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-23-008072 · doc4.xml · derivative · entry 10 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 582,779 Underlying: Common Stock · 14,000 shares Expires 2029-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F6 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after April 23, 2019, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| February 08, 2023 Filed Feb 9, 2023 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $20.98 | $293,720.00 |
DisclosureSEC source: 0001209191-23-008072 · doc4.xml · nonDerivative · entry 4 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $20.73 to $21.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 08, 2023 Filed Feb 9, 2023 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $5.04 | $70,560.00 |
DisclosureSEC source: 0001209191-23-008072 · doc4.xml · nonDerivative · entry 3 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-23-008072 · doc4.xml · derivative · entry 9 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,779 Underlying: Common Stock · 14,000 shares Expires 2029-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F6 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after April 23, 2019, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $21.45 | $300,300.00 |
DisclosureSEC source: 0001209191-23-008072 · doc4.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.25 to $21.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $5.04 | $70,560.00 |
DisclosureSEC source: 0001209191-23-008072 · doc4.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 01:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-23-004127 · doc4.xml · derivative · entry 11 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,779 Underlying: Common Stock · 28,000 shares Expires 2029-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F5 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after April 23, 2019, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 01:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 28,000 | $20.02 | $560,560.00 |
DisclosureSEC source: 0001209191-23-004127 · doc4.xml · nonDerivative · entry 6 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,554 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $20 to $20.41. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 01:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 28,000 | $5.04 | $141,120.00 |
DisclosureSEC source: 0001209191-23-004127 · doc4.xml · nonDerivative · entry 5 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 01:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-23-004127 · doc4.xml · derivative · entry 10 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,779 Underlying: Common Stock · 28,000 shares Expires 2029-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F5 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after April 23, 2019, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 01:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 28,000 | $20.87 | $584,360.00 |
DisclosureSEC source: 0001209191-23-004127 · doc4.xml · nonDerivative · entry 4 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,554 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.35 to $21.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 01:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 28,000 | $5.04 | $141,120.00 |
DisclosureSEC source: 0001209191-23-004127 · doc4.xml · nonDerivative · entry 3 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 701,680 | $0.00 Strike: $20.45 | $0.00 |
DisclosureSEC source: 0001209191-23-004127 · doc4.xml · derivative · entry 13 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 701,680 Underlying: Common Stock · 701,680 shares Expires 2033-01-16 F7 · derivative.exercise_date: Such option was granted pursuant to the terms of the Issuer's 2020 Stock Option and Incentive Plan and becomes exercisable, if at all, in twelve equal quarterly installments if the last quoted trading price per share of the Issuer's common stock on the Nasdaq Global Market during any fifteen consecutive calendar day period is at least $35.00; provided that the reporting person maintains a service relationship with the Issuer. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 701,680 | $0.00 Strike: $20.45 | $0.00 |
DisclosureSEC source: 0001209191-23-004127 · doc4.xml · derivative · entry 12 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 701,680 Underlying: Common Stock · 701,680 shares Expires 2033-01-16 F6 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 17, 2023, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-23-004127 · doc4.xml · derivative · entry 9 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,779 Underlying: Common Stock · 28,000 shares Expires 2029-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F5 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after April 23, 2019, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 28,000 | $20.23 | $566,440.00 |
DisclosureSEC source: 0001209191-23-004127 · doc4.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,554 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.